Homa Yeganegi
Chief Tech/Sci/R&D Officer bei AGENUS INC.
Profil
Homa Yeganegi ist Senior Vice President & Head-Medical Affairs bei Turning Point Therapeutics, Inc. Zuvor hatte sie die Position des Vice President-Global Scientific & Medical Affairs bei Halozyme Therapeutics, Inc. und Senior Vice President-Global Medical Affairs bei Clovis Oncology, Inc. inne. Sie erhielt einen Bachelor-Abschluss von der Universität von Teheran und einen Master-Abschluss von der University of Western Australia.
Aktive Positionen von Homa Yeganegi
Unternehmen | Position | Beginn |
---|---|---|
AGENUS INC. | Chief Tech/Sci/R&D Officer | 20.07.2023 |
Ehemalige bekannte Positionen von Homa Yeganegi
Unternehmen | Position | Ende |
---|---|---|
TURG POIN | Corporate Officer/Principal | - |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - |
HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Homa Yeganegi
The University of Western Australia | Graduate Degree |
University of Tehran | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AGENUS INC. | Health Technology |
HALOZYME THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |